PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT03140488 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-12-20, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT01439997 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-12-15, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01143246 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT02770716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT01796301 at 2026-07-30T19:32:59.853Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT03479762 at 2026-07-30T19:32:59.846Z. Its registry update date was 2022-11-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01568866 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-11-14, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04105998 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT04750460 at 2026-07-30T19:32:59.860Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT03590119 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-11-08, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT04042142 at 2026-07-30T19:32:59.855Z. Its registry update date was 2022-11-04, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT04465396 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-10-04, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT03416374 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-27, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT02412878 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-23, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01080391 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04959799 at 2026-11-16T17:37:42.807Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT03456687 at 2026-07-30T19:35:26.142Z. Its registry update date was 2022-09-16, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT05533008 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-09-08, and PeptideScanner's reviewed identity mapping was difelikefalin.
PeptideScanner retained ClinicalTrials.gov record NCT04764968 at 2026-11-16T01:42:39.027Z. Its registry update date was 2022-09-07, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03255629 at 2026-07-30T19:35:26.311Z. Its registry update date was 2022-09-06, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT01229943 at 2026-07-30T19:36:31.409Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04978051 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT02748369 at 2026-07-30T19:36:31.410Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03373435 at 2026-11-16T01:46:44.871Z. Its registry update date was 2022-07-18, and PeptideScanner's reviewed identity mapping was avexitide.
PeptideScanner retained ClinicalTrials.gov record NCT04590586 at 2026-11-15T21:46:36.651Z. Its registry update date was 2022-06-29, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04007809 at 2026-07-30T19:38:43.098Z. Its registry update date was 2022-06-28, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT03422666 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-06-14, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00775684 at 2026-07-30T19:38:43.099Z. Its registry update date was 2022-06-07, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT04397718 at 2026-11-15T21:52:09.579Z. Its registry update date was 2022-06-06, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT03463993 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-06-01, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT03029234 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03442972 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03268811 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-05-24, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02010385 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-23, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03520569 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-13, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02664441 at 2026-07-30T19:39:59.673Z. Its registry update date was 2022-05-05, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03138252 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-05-04, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT03422653 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin.
PeptideScanner retained ClinicalTrials.gov record NCT03636269 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin.
PeptideScanner retained ClinicalTrials.gov record NCT02268175 at 2026-07-30T19:40:58.917Z. Its registry update date was 2022-04-19, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02765399 at 2026-07-30T19:40:58.914Z. Its registry update date was 2022-04-12, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01578239 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT03973047 at 2026-07-30T19:40:58.916Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was bremelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT00754442 at 2026-07-30T19:40:58.915Z. Its registry update date was 2022-04-01, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04654351 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-03-29, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT03500549 at 2026-11-16T01:37:14.654Z. Its registry update date was 2022-03-25, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT03795558 at 2026-11-15T22:07:29.454Z. Its registry update date was 2022-03-23, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT05288465 at 2026-11-16T17:33:14.861Z. Its registry update date was 2022-03-21, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03201419 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-03-02, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT03342001 at 2026-11-15T21:54:02.201Z. Its registry update date was 2022-02-21, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.
PeptideScanner retained ClinicalTrials.gov record NCT02487797 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-02-11, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00724789 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-02-03, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT02980666 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-02-02, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02586675 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-01-21, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03085095 at 2026-07-30T19:44:52.972Z. Its registry update date was 2022-01-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02849990 at 2026-11-15T21:52:09.579Z. Its registry update date was 2022-01-13, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT03300518 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-01-11, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT02122198 at 2026-07-30T19:44:52.962Z. Its registry update date was 2022-01-10, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03262610 at 2026-07-30T19:44:52.963Z. Its registry update date was 2022-01-04, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03659578 at 2026-11-15T22:10:40.222Z. Its registry update date was 2022-01-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.